What is Competitive Landscape of Elekta Company?

Elekta Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How does Elekta stack up against Varian and other rivals?

Elekta, founded in 1972 in Stockholm, evolved from radiosurgery to a global oncology-tech provider with MR‑Linac and software-led offerings. Recent AI planning and MOSAIQ updates aim to boost recurring revenue and adaptive therapy adoption.

What is Competitive Landscape of Elekta Company? Elekta competes intensely with Varian (Siemens Healthineers), Accuray and other specialists across hardware, AI-enabled planning and oncology IT; key differentiators are MR‑Linac installs, software subscriptions and service reach. See Elekta Porter's Five Forces Analysis for detailed forces.

Elekta designs and supplies advanced radiation therapy and oncology informatics, focusing on precision radiotherapy (linacs, MR‑guided systems), stereotactic radiosurgery and brachytherapy while increasing recurring revenue from services and software.

Global market standing

Elekta is widely regarded as the #2 global player in radiation therapy with an estimated 25–30% share of the global linac installed base and dominant leadership in cranial SRS.

Flagship product clusters

Key lines include EBRT linacs (Versa HD, Harmony), MR‑guided Unity, Leksell Gamma Knife Icon/Esprit, brachytherapy solutions and oncology informatics (MOSAIQ Plaza, Elekta ONE, Monaco, ProKnow).

MR‑guided leadership

Unity MR‑Linac, co‑developed with Philips, surpassed 150 global installations by 2024–2025, positioning Elekta as a leader in MR‑guided radiotherapy.

SRS dominance

Leksell Gamma Knife holds over 80% share of dedicated cranial SRS systems, reinforcing Elekta’s stereotactic radiosurgery leadership worldwide.

Geographic footprint is balanced across EMEA, North America and APAC, with historic strength in EMEA and emerging markets (China, India, Middle East) and improving North American momentum driven by fleet refresh cycles and cancer care investments.

Competitive strengths and challenges

Elekta’s position combines product breadth, clinical differentiation in adaptive/SRS care, and growing recurring revenue from services and software; FY2023/24 net sales were approximately SEK 15–17 billion.

• Strength: SRS market leadership via Leksell Gamma Knife (cranial SRS >80% share).
• Strength: Early MR‑Linac adoption — Unity >150 installations by 2024–2025.
• Strength: Comprehensive brachytherapy portfolio (Nucletron heritage), top‑two globally.
• Weakness: Lower U.S. linac market share versus Varian; regional competition in China; Accuray competition in SRS/SBRT niches.

Positioning strategy emphasizes premium adaptive and stereotactic segments while expanding mid‑tier options (Harmony) for cost‑sensitive markets; software and service growth reduces revenue cyclicality and capitalizes on government radiotherapy investments across EU, UK and China.

For historical context and corporate evolution see Brief History of Elekta.

Elekta SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Revenue for the company derives from capital equipment sales (linacs, MR‑linac), service contracts, software/licenses, and disposables; recurring service and software maintenance generated ~55–65% of after‑sales gross margins for comparable vendors in 2024, with financing and bundled fleet deals boosting large account ARR.

Monetization emphasizes long‑term service agreements, cloud/AI platform subscriptions, and clinical consumables; strategic alliances accelerate cross‑sell into imaging and oncology IT channels.

Varian (Siemens Healthineers)

Global leader in linacs, treatment planning (Eclipse) and oncology IT (ARIA) with a vast installed base and service network.

Competitive Strengths

Integrated Siemens imaging, AI planning and enterprise deals enable bundled fleets, financing and end‑to‑end workflows that pressure peers in tenders.

Accuray

Specializes in precision SRS/SBRT with CyberKnife and TomoTherapy/Radixact; competes on hypofractionation accuracy and robotic targeting.

Proton vendors (IBA, Mevion)

Proton therapy represents indirect competition for capital allocation; flagship proton centers can displace some linac purchases despite photons remaining the global volume workhorse.

GE HealthCare & Philips

Indirect competition via imaging and informatics ecosystems; Philips collaborates on MR‑linac while also partnering with other RT vendors.

Regional & Emerging Players

China/APAC low‑to‑mid tier linac vendors (e.g., Shinva, Canon Medical) exert price pressure in price‑sensitive tenders and via local manufacturing policies.

Consolidation, alliances and tech pivots reshape the Elekta competitive landscape: Siemens‑Varian integration, Philips collaboration on MR‑linac, cloud/AI partnerships (Elekta with Microsoft Azure and Varian cloud platforms) and ViewRay’s exit redistributed MR‑guided RT opportunities between Unity and Varian adaptive solutions; see Mission, Vision & Core Values of Elekta.

Key implications for market position

How competitors drive procurement, pricing and technology choices across hospital systems and cancer centers.

• Varian/Siemens bundling increases barriers for single‑vendor deals and drives price/finance competition.
• Accuray’s gains in Japan/EU pressure radiosurgery accounts where Elekta previously led.
• Proton centers (IBA/Mevion) shift capital spend away from photon upgrades in select markets.
• Regional vendors create price‑led share erosion in APAC and China tender markets.

Elekta PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Key milestones include development of the Unity MR-Linac and acquisition of legacy brachytherapy assets, strengthening Elekta’s multi-modality oncology footprint. Strategic moves emphasize integrated software (MOSAIQ Plaza, Elekta ONE) and service expansion across EMEA and emerging markets, creating durable customer lock-in.

Competitive edge rests on MR-guided adaptive therapy, sub-millimetric cranial SRS with Leksell Gamma Knife Esprit, broad brachytherapy offerings from Nucletron, and a large installed base supporting recurring service revenues.

Technological Differentiation

Unity MR-Linac enables on‑table MR imaging and daily adaptation for complex anatomical sites, while Leksell Gamma Knife Esprit delivers sub‑millimetric cranial SRS with extensive clinical evidence.

Multi‑Modality Stickiness

Nucletron legacy assets supply HDR afterloaders and applicators, creating cross‑departmental adoption that complements external beam radiotherapy fleets and increases switching costs.

Software & Ecosystem

MOSAIQ Plaza and Elekta ONE integrate OIS, Monaco TPS, QA (ProKnow) and analytics, generating recurring software revenue and enhancing customer retention via interoperable workflows.

Installed Base & Service Reach

Strong EMEA and emerging‑market service networks support repeat orders and multi‑year contracts; the value-tier Harmony linac expands addressable market with lower total cost of ownership.

Moats, Risks and Market Context

Elekta’s IP portfolio and clinical partnerships support premium positioning but face pressure from AI planning diffusion and competitors’ adaptive RT advances. Financial and market data underpinning strategic choices are visible in service revenue trends and installed‑base metrics.

• IP: Dozens of patents around MR‑guided workflows, stereotactic delivery and planning algorithms.
• Clinical evidence: Unity and Gamma Knife supported by peer‑reviewed outcome publications driving hospital adoption.
• Revenue model: Recurring service and software subscriptions increase lifetime customer value; see Revenue Streams & Business Model of Elekta.
• Competitive pressures: Varian (Siemens Healthineers overlap in imaging/RT), startups advancing AI planning, and faster adaptive RT rollouts challenge market share.

Elekta Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Elekta’s industry position sits strong in precision radiotherapy and adaptive workflows, supported by a diversified product portfolio and growing software/services revenue; risks include pricing pressure, regulatory/cybersecurity compliance costs, and aggressive competition from integrated rivals. The future outlook hinges on accelerating Unity MR-Linac adoption, expanding North American penetration, and scaling cloud/AI services to boost recurring margins while defending share in APAC/EMEA tender markets.

Industry Trend: Rising Cancer Incidence

Global cancer cases are projected to rise ~20% from 2020–2030, sustaining long-term demand for radiotherapy equipment and software, particularly in capacity-constrained emerging markets.

Therapy Shift: Hypofractionation & Adaptive RT

Movement toward hypofractionation, image-guided, and adaptive radiotherapy increases demand for MR-guided systems, high-definition MLCs, and advanced treatment planning/QA solutions.

Digitalization & AI-Driven Workflows

Hospital digitalization is accelerating need for integrated OIS/TPS, cloud platforms, and AI-driven planning/QA — areas where software like Elekta ONE and MOSAIQ Plaza can expand recurring revenue.

Capital & Geopolitical Drivers

Government programs in the EU, UK, and China and post-pandemic supply-chain normalization are shaping capital budgets and purchase timing for linac replacements and new builds.

Competitive dynamics intensify as Varian integrated with Siemens’ broader imaging/IT ecosystem pressures pricing and enterprise deals; proton therapy grows selectively but photons remain the cost-effective mainstream.

Future Challenges

Key headwinds that could affect Elekta’s market position include pricing pressure in tenders, regulatory and cybersecurity compliance costs, and technological commoditization of AI planning.

• Intensifying competition from Varian/Siemens ecosystem and aggressive enterprise contracting.
• Price-sensitive tender environments in APAC and EMEA compress margins and complicate fleet refresh strategies.
• Regulatory, software safety, and cybersecurity compliance raise R&D and post-market surveillance costs.
• AI planning commoditization and alternative adaptive solutions may narrow product differentiation.

Opportunities center on MR-guided RT scale-up, stereotactic program expansion, software/services monetization, and emerging market tenders that support linac volumes.

Growth Opportunities

Concrete growth levers can increase Elekta’s market share and recurring revenue mix, leveraging clinical evidence and platform partnerships.

• MR-Linac adoption: Unity installations have surpassed 150, supporting evidence-driven adoption and expanded indications.
• Stereotactic radiotherapy: Gamma Knife and high-definition MLC linacs open expansion in cranial/body SBRT programs.
• Software & cloud: Elekta ONE, MOSAIQ Plaza, and ProKnow-style analytics can lift recurring software/services margins.
• Emerging markets & China: Multi-year linac expansion programs in China plus tenders in India, Middle East, and Africa support Harmony/Versa HD volume growth.

Strategic imperatives include competitive pricing for fleet refreshes, faster North America penetration for Unity, open interoperability, and partnerships across imaging, AI, cloud, and dosimetry to sustain differentiation versus closed-platform rivals; see market context in Target Market of Elekta.

Elekta Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔